Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boulware

Showing results (811-820 of 832) with videos related to

Pageof 84
Sort By:
Medrxiv : the Preprint Server for Health Sciences|May 27, 2024
Effect of Montelukast vs Placebo on Time to Sustained Recovery in Outpatients with COVID-19: The ACTIV-6 Randomized Clinical TrialRussell L Rothman, Thomas G Stewart, Ahmad Mourad, et al.
The Lancet. Infectious Diseases|September 29, 2024
Advancing the chemotherapy of tuberculous meningitis: a consensus viewSean Wasserman, Joseph Donovan, Evelyne Kestelyn, et al.
JAMA Network Open|October 18, 2024
Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical TrialRussell L Rothman, Thomas G Stewart, Ahmad Mourad, et al.
BMJ Open|April 4, 2019
AMBIsome Therapy Induction OptimisatioN (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence studyPonego Lloyd Ponatshego, David Stephen Lawrence, Nabila Youssouf, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 20, 2022
Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination and Booster on Coronavirus Disease 2019 (COVID-19) Symptom Severity Over Time in the COVID-OUT TrialDavid R Boulware, Thomas A Murray, Jennifer L Proper, et al.
Journal of General Internal Medicine|November 10, 2019
Hypertension Self-management in Socially Disadvantaged African Americans: the Achieving Blood Pressure Control Together (ACT) Randomized Comparative Effectiveness TrialL Ebony Boulware, Patti L Ephraim, Felicia Hill-Briggs, et al.
The Lancet. Infectious Diseases|June 11, 2023
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trialCarolyn T Bramante, John B Buse, David M Liebovitz, et al.
The New England Journal of Medicine|March 23, 2022
Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal MeningitisJoseph N Jarvis, David S Lawrence, David B Meya, et al.
The New England Journal of Medicine|September 7, 2022
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19Carolyn T Bramante, Jared D Huling, Christopher J Tignanelli, et al.
The American Journal of Tropical Medicine and Hygiene|July 16, 2024
Diagnostic Prediction Model for Tuberculous Meningitis: An Individual Participant Data Meta-AnalysisAnna M Stadelman-Behar, Nicki Tiffin, Jayne Ellis, et al.
Pageof 84

Showing results (811-820 of 832) with videos related to

Sort By:
Pageof 84
Medrxiv : the Preprint Server for Health Sciences|May 27, 2024
Effect of Montelukast vs Placebo on Time to Sustained Recovery in Outpatients with COVID-19: The ACTIV-6 Randomized Clinical TrialRussell L Rothman, Thomas G Stewart, Ahmad Mourad, et al.
The Lancet. Infectious Diseases|September 29, 2024
Advancing the chemotherapy of tuberculous meningitis: a consensus viewSean Wasserman, Joseph Donovan, Evelyne Kestelyn, et al.
JAMA Network Open|October 18, 2024
Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical TrialRussell L Rothman, Thomas G Stewart, Ahmad Mourad, et al.
BMJ Open|April 4, 2019
AMBIsome Therapy Induction OptimisatioN (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence studyPonego Lloyd Ponatshego, David Stephen Lawrence, Nabila Youssouf, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 20, 2022
Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination and Booster on Coronavirus Disease 2019 (COVID-19) Symptom Severity Over Time in the COVID-OUT TrialDavid R Boulware, Thomas A Murray, Jennifer L Proper, et al.
Journal of General Internal Medicine|November 10, 2019
Hypertension Self-management in Socially Disadvantaged African Americans: the Achieving Blood Pressure Control Together (ACT) Randomized Comparative Effectiveness TrialL Ebony Boulware, Patti L Ephraim, Felicia Hill-Briggs, et al.
The Lancet. Infectious Diseases|June 11, 2023
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trialCarolyn T Bramante, John B Buse, David M Liebovitz, et al.
The New England Journal of Medicine|March 23, 2022
Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal MeningitisJoseph N Jarvis, David S Lawrence, David B Meya, et al.
The New England Journal of Medicine|September 7, 2022
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19Carolyn T Bramante, Jared D Huling, Christopher J Tignanelli, et al.
The American Journal of Tropical Medicine and Hygiene|July 16, 2024
Diagnostic Prediction Model for Tuberculous Meningitis: An Individual Participant Data Meta-AnalysisAnna M Stadelman-Behar, Nicki Tiffin, Jayne Ellis, et al.
Pageof 84